Anavex Life Sciences Corp. (AVXL) stock has experienced significant volatility and a substantial decline over the past six months, losing approximately 84.5% over the past 12 months and roughly 44% in the 30 days leading up to late October 2026. Key events impacting the stock price include: The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on blarcamesine for Alzheimer's disease in December 2025, leading Anavex to withdraw its European marketing authorization application in March 2026, which created significant uncertainty regarding the drug's path to market. On May 6, 2026, Anavex reported that its CEO, Christopher Missling, PhD, was terminated for cause, effective immediately, due to conduct inconsistent with company policy, causing the stock price to fall by 6.59% on May 7, 2026, and another 5.55% on May 12, 2026. On August 28, 2026, Anavex filed an amended Annual Report disclosing a material weakness in internal control over financial reporting at September 30, 2025, and that the company's disclosure controls and procedures were not effective, leading to a 6.35% drop in the stock price on August 31, 2026. Multiple securities class-action lawsuits have been filed against Anavex, alleging misleading statements about inadequate internal controls and regulatory challenges due to former CEO Christopher Missling's misconduct, with a lead-plaintiff deadline of November 30, 2026, adding to negative sentiment. Anavex Life Sciences named Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and a member of the Board of Directors on November 3, 2026.